Kendomycin
Подписчиков: 0, рейтинг: 0
|
| |
| Names | |
|---|---|
|
IUPAC name
(1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.16,9.02,7]tetracosa-2,5,7,14-tetraen-4-one
| |
|
Systematic IUPAC name
(1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.16,9.02,7]tetracosa-2,5,7,14-tetraen-4-one | |
| Other names
(-)-TAN 2162
| |
| Identifiers | |
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider |
|
| MeSH | C485395 |
|
PubChem CID
|
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C29H42O6 | |
| Molar mass | 486.64 g/mol |
| Appearance | Yellow powder |
| Solubility in DMSO, methanol | Soluble |
| Hazards | |
| Occupational safety and health (OHS/OSH): | |
|
Main hazards
|
Toxic |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Kendomycin is an anticancer macrolide first isolated from Streptomyces violaceoruber. It has potent activity as an endothelin receptor antagonist and anti-osteoporosis agent. It also has strong cytotoxicity against various tumor cell lines.
Total synthesis
Because of its potent biological activities, kendomycin has attracted interest as a target of total synthesis. The first total synthesis of kendomycin was accomplished by Lee and Yuan in 2004. The total number of syntheses stands at 6.